Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-DTPA-omburtamab
- Development stage
- Phase 2
- Lead developer
- Y-mAbs Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intrathecal
01
Overview
**177Lu-DTPA-omburtamab** is an investigational B7-H3-directed radioimmunoconjugate comprising the murine IgG1 monoclonal antibody omburtamab, linked through the chelator diethylenetriaminepentaacetic acid to the beta-emitting radionuclide lutetium-177. Following intracerebroventricular administration, omburtamab binds B7-H3, also known as CD276, on tumor cells and concentrates lutetium-177 radiation at the tumor site, producing localized cytotoxic beta radiation. The asset was developed from an omburtamab program originally developed at Memorial Sloan Kettering Cancer Center and licensed to Y-mAbs Therapeutics; current clinical investigation includes pediatric B7-H3-expressing primary or metastatic central nervous system tumors. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lutetium-lu-177-dtpa-omburtamab))
- Brand names
- Omblastys
- Other names
- 177Lu-omburtamab-DTPAlutetium Lu 177-DTPA-omburtamab
02
Targets
B7-H3
Beyond the preview
Go deeper on 177Lu-DTPA-omburtamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-DTPA-omburtamab.